Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Recommendation that trial escalate to next dose level of 8mg tablet --Initial interim clinical data from first two cohorts expe...
Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(0.66) per share. This is a 82.21 percent increase over losse...
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company...
-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid t...
-- Demonstrates PAS-004's potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD...
Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(1.61) per share. This is a 56.49 percent increase over losse...
